Here to walk us through the available treatment options for psoriasis, psoriatic arthritis and atopic dermatitis is Dr. April Armstrong. She is interviewed by Dr. John Russell, who is also joined by a patient sharing her experience of living with psoriatic disease.

Crisaborole and dupilumab are two of the newest therapies to become part of the atopic dermatitis treatment landscape, so here to provide guidance on how we can apply them—and even how they may lead the way to more targeted treatments in the future—are allergist Dr. Anna Fishbein and dermatologist Dr. Lindsay Strowd.

Content update: Since the release of this activity, dupilumab has been FDA-approved for use in children ages 6 through 11 (May 2020) and crisaborole has been FDA-approved for infants ages 3 months and older (March 2020).

There are many challenges clinicians face when diagnosing atopic dermatitis, but reaching an accurate diagnosis is essential in not only beginning treatment sooner, but also in managing its comorbidities. Joining Dr. Jennifer Caudle are allergist Dr. Anna Fishbein and dermatologist Dr. Lindsay Strowd, who use a patient case to demonstrate their approach to diagnosing atopic dermatitis.

Content update: Since the release of this activity, dupilumab has been FDA-approved for use in children ages 6 through 11 (May 2020) and crisaborole has been FDA-approved for infants ages 3 months and older (March 2020).

Approximately 40% of patients with HR+ breast cancer harbor PIK3CA mutations, which are associated with a poor prognosis. The phosphoinositide 3-kinase (PI3K) pathway is the most frequently altered pathway in breast cancer and has been associated with resistance to endocrine therapy and disease progression. PI3K inhibitor combination therapy has shown activity in patients with PIK3CA mutation–positive HR+/HER2− breast cancer after showing moderate efficacy and limited tolerability in clinical trials as monotherapy.

This activity will review the most recent clinical data and evidence-based updates and provide expert insights on PI3K inhibitors for HR+/HER2− advanced or metastatic breast cancer.

From a lack of treatment options to frequent relapses after surgery, biliary tract carcinoma is challenging to treat. However, there are treatment options on the horizon that can potentially change the treatment landscape, as world-renowned thought leader Dr. Do-Youn Oh explains.

There are several targeted agents that have been approved by the Food & Drug Administration (FDA) for the treatment of renal cell carcinoma (RCC). Although targeted therapies have improved patient outcomes, they do not achieve a durable complete response. Now, immune checkpoint inhibitors are gaining FDA approvals in RCC, with additional immunotherapeutic agents being studied in RCC, including combination strategies with targeted therapy and other immunotherapies.

Clinical decision-making concerning sequencing of therapies for patients with RCC has become much more complex in the era of ever-increasing treatment options and advances in clinical trial research. Translating the most effective strategies for optimizing patient outcomes across multiple lines of therapy is becoming increasingly challenging for clinicians given the vast amount of new information. The emergence of immunotherapeutic and targeted compounds has raised many questions about how to optimize patient outcomes by the effective selection, timing, combination, and optimal sequencing of these agents.

This activity will review clinical advances and emerging research for immunotherapeutic agents and combination strategies for the treatment of advanced renal cell carcinoma, including FDA-approved immunotherapies, guideline recommendations, recent clinical trial data on immunotherapy combination strategies, and adverse event management.

As the burden of HPV-associated cancers like cervical cancer and oropharyngeal cancers, which are a subset of squamous cell cancer of the head and neck (SCCHN), continues to grow, are there emerging treatments that may lead to more optimal outcomes? Join oncology experts in both areas of focus as they discuss treatment approaches for SCCHN and cervical cancer.

Hemophilia A is a rare bleeding disorder caused by deficiency of clotting factor VIII. The current standard of care for patients with severe hemophilia A centers on replacement therapy with factor VIII concentrate, either on demand when bleeding occurs or prophylactically (replacement therapy). Potential complications from replacement therapy include the development of inhibitory antibodies that attack the clotting factor in approximately one-fourth of patients, viral infections from human clotting factors, and bleeding in joints and muscles resulting from treatment delays. According to treatment guidelines from the Medical and Scientific Advisory Council (MASAC), “Inhibitor development is the most severe complication of treatment for patients with inherited hemophilia A.” In addition, the high cost and frequency of infusing factor VIII concentrates can increase the potential for side effects, thereby negatively affecting patient quality of life.

Fortunately, several unique agents have been newly approved or are currently under development. These agents promise to reduce morbidity and improve quality of life for patients. Clinicians will be challenged to integrate these new agents into their clinical practices.

AXIS routinely collects and analyzes data gathered from participants in our live grand rounds programs. These questions provide incredible insight regarding the persistent challenges that clinicians face when …=

Hemophilia A is a rare bleeding disorder caused by deficiency of clotting factor VIII. The current standard of care for patients with severe hemophilia A centers on replacement therapy with factor VIII concentrate, either on demand when bleeding occurs or prophylactically (replacement therapy). Potential complications from replacement therapy include the development of inhibitory antibodies that attack the clotting factor in approximately one-fourth of patients, viral infections from human clotting factors, and bleeding in joints and muscles resulting from treatment delays. According to treatment guidelines from the Medical and Scientific Advisory Council (MASAC), “Inhibitor development is the most severe complication of treatment for patients with inherited hemophilia A.” In addition, the high cost and frequency of infusing factor VIII concentrates can increase the potential for side effects, thereby negatively affecting patient quality of life.

Fortunately, several unique agents have been newly approved or are currently under development. These agents promise to reduce morbidity and improve quality of life for patients. Clinicians will be challenged to integrate these new agents into their clinical practices.

AXIS routinely collects and analyzes data gathered from participants in our live grand rounds programs. These questions provide incredible insight regarding the persistent challenges that clinicians face when ...

There are limited treatment options in the first-line setting for patients with advanced ovarian cancer. Many patients experience disease recurrence or progression with first-line chemotherapy, with approximately 10% to 30% experiencing long-term survival.

Anti-angiogenesis agents, such as bevacizumab and nintedanib, have been investigated in clinical trials for the first-line treatment of patients with advanced ovarian cancer. Bevacizumab is now FDA approved in combination with carboplatin and paclitaxel, followed by bevacizumab as a single agent, for the treatment of women with stage III or stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection.

AXIS routinely collects and analyzes data gathered from participants in our live grand rounds programs. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment planning to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent grand rounds series on anti-angiogenesis agents for the first-line treatment of advanced ovarian cancer.